Molecular genetic classification of endometrial cancer in the context of personalised medicine

Cover Page

Cite item

Full Text

Abstract

The article presents a new classification of endometrial cancer developed by the International Federation of Gynecology and Obstetrics (FIGO): FIGO 2023. Literature search was performed in the PubMed, Medline, RSCI (Russian Science Citation Index) databases using key words “endometrial cancer”, “molecular genetic study”, “FIGO 2023”, “POLE gene mutations”, “dMMR status”, “ТР53 gene”, “NSMP”. In total, 206 articles were found (published between 1983 and 2024), the more significant articles (45) were included in this literature review. The renewed FIGO 2023 classification contains 19 endometrial cancer substages: 5 are included in stage I, 3 in stage II, 8 in stage III, 3 in stage IV. The main differences of the new classification from FIGO 2009 are the specification of tumor type (aggressive/non-aggressive), level of lymphovascular involvement, presence of macro- or micrometastases in the lymph nodes, as well as characteristics of molecular and genetic markers. According to the new FIGO 2023 classification, change of stage is recommended depending on the presence of mutations in the POLE and ТР53 genes. Thus, stage IA includes tumors with favorable prognosis and mutation in the POLE gene (stage IAmPOLEmut), stage IIC includes tumors with unfavorable prognosis and mutation in the ТР53 gene (stage IICmp53abn). According to the data of trials, the identified substages – which take into account molecular profile of the tumor – significantly differ in terms of oncological outcomes of disease progression.

Therefore, introduction of the new FIGO 2023 classification taking into account molecular biology features of the tumor will allow to adopt a more targeted approach to management of patients with endometrial cancer and to make predictions on disease progression. One of the remaining important questions is further study of long-term results of adjuvant therapy.

About the authors

L. N. Lyubchenko

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of National Medical Research Radiological Centre, Ministry of Health of Russia; National Medical Research Radiological Centre, Ministry of Health of Russia

Author for correspondence.
Email: clingen@mail.ru
ORCID iD: 0000-0002-1711-8334

Lyudmila Nikolaevna Lyubchenko

51 3rd Parkovaya St., Moscow 105425

4 Koroleva St., Obninsk 249036

Russian Federation

S. V. Mukhtarulina

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of National Medical Research Radiological Centre, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-7481-9631

51 3rd Parkovaya St., Moscow 105425

Russian Federation

M. A. Meshkova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of National Medical Research Radiological Centre, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-3961-921X

51 3rd Parkovaya St., Moscow 105425

Russian Federation

Z. A. Sidakova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of National Medical Research Radiological Centre, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0009-0007-2024-9064

51 3rd Parkovaya St., Moscow 105425

Russian Federation

N. N. Volchenko

P.A. Hertzen Moscow Oncology Research Institute – branch of National Medical Research Radiological Centre, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-0421-4172

3 2nd Botkinsky Proezd, Moscow 125284

Russian Federation

E. G. Novikova

P.A. Hertzen Moscow Oncology Research Institute – branch of National Medical Research Radiological Centre, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-3537-6377

3 2nd Botkinsky Proezd, Moscow 125284

Russian Federation

References

  1. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. (In Russ.).
  2. Berek J.S., Matias-Guiu X., Creutzberg C. et al. Endometrial cancer staging subcommittee, FIGO Women’s Cancer Committee. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383–94. doi: 10.1002/ijgo.14923
  3. Bokhman Ya.V. Clinical practice guidelines on gynaecological cancers. Leningrad, 1989. 462 p. (In Russ.).
  4. Talhouk A., McAlpine J.N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 2016;13(3):14. doi: 10.1186/s40661-016-0035-4
  5. Santoro A., Angelico G., Travaglino A. et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers (Basel) 2021;13(11):2623. doi: 10.3390/cancers13112623
  6. Eriksson L.S., Nastic D., Lindqvist P.G. et al. Combination of proactive molecular risk classifier for endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer. Ultrasound Obstet Gynecol 2021;58(3):457–68. doi: 10.1002/uog.23573
  7. León-Castillo A., de Boer S.M., Powell M.E. et al. TransPORTEC consortium. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38(29):3388–97. doi: 10.1200/JCO.20.00549
  8. León-Castillo A., Gilvazquez E., Nout R. et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020;250(3):312–22. doi: 10.1002/path.5373
  9. Vermij L., Smit V., Nout R., Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2020;76(1):52–63. doi: 10.1111/his.14015
  10. Van den Heerik A., Horeweg N., Nout R.A. et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020;30(12):2002–7. doi: 10.1136/ijgc-2020-001929
  11. Ma X., Dong L., Liu X. et al. POLE/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res 2022;41(1):216. doi: 10.1186/s13046-022-02422-1
  12. Travaglino A., Raffone A., Mollo A. et al. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma. Arch Gynecol Obstet 2020;301(5):1117–25. doi: 10.1007/s00404-020-05531-4
  13. León-Castillo A., Britton H., McConechy M.K. et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 2019;250(3):323–35. doi: 10.1002/path.5372
  14. Van Gool I.C., Eggink F.A., Freeman-Mills L. et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015;21(14):3347–55. doi: 10.1158/1078-0432.CCR-15-0057
  15. Raskin G.A., Mukhina M.S., Kaurtseva A.S. et al. Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites. Arkhiv patologii = Russian Journal of Archive of Pathology 2023;85(1):36–42. (In Russ.). doi: 10.17116/patol20238501136
  16. Bosquet J.G., Zhang Q., Cliby W.A. et al. Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. PLoS One 2021;16(1):e0245664. doi: 10.1371/journal.pone.0245664
  17. Demidova I.A., Filipenko M.L., Tsukanov A.S., Imyanitov E.N. Microsatellite instability: nuances of laboratory diagnostics (position of the Interregional Organization of Molecular Geneticists in Oncology and Oncohematology). Voprosy onkologii = Issues of Oncology 2023;69(2):174–9. (In Russ.). doi: 10.37469/0507-3758-2023-69-2-174-179
  18. Jumaah A.S., Al-Haddad H.S., McAllister K.A. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: a systematic review and meta analysis. PLoS One 2022;17(2): e0263585. doi: 10.1371/journal.pone.0263585
  19. Concin N., Matias-Guiu X., Vergote I. et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch 2021;478(2):153–90. doi: 10.1007/s00428-020-03007-z
  20. Swift B.E., Gien L.T. Incorporating molecular diagnostics into treatment paradigms for endometrial cancer. Curr Treat Options Oncol 2022;23(8):1121–34. doi: 10.1007/s11864-022-00993-x
  21. Momeni-Boroujeni A., Dahoud W., Vanderbilt C.M. et al. Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res 2021;27(9):2613–23. doi: 10.1158/1078-0432.CCR-20-4436
  22. Travaglino A., Raffone A., Mascolo M. et al. Clear cell endometrial carcinoma and the TCGA classification. Histopathology 2020;76(2):336–8. doi: 10.1111/his.13976
  23. Kim S.R., Cloutier B.T., Leung S. Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gynecol Oncol 2020;158(1):3–11. doi: 10.1016/j.ygyno.2020.04.043
  24. Yano M., Ito K., Yabuno A. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. Mod Pathol 2019;32:1023–31. doi: 10.1038/s41379-019-0220-1
  25. Bosse T., Nout R.A., McAlpine J.N. et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 2018;42(5):561–8. doi: 10.1097/PAS.0000000000001020
  26. Stelloo E., Nout R.A., Osse E.M. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22(16):4215–24. doi: 10.1158/1078-0432.CCR-15-2878
  27. Momeni-Boroujeni A., Nguyen B., Vanderbilt C.M. et al. Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol 2022;35(9):1269–78. doi: 10.1038/s41379-022-01066-y
  28. Nagel J., Paschoalini R.B., Barreto P.S.D. et al. Predictive biomarkers in endometrial carcinomas: a review of their relevance in daily anatomic pathology. Surg Exp Pathol 2024;7:21. doi: 10.1186/s42047-024-00164-2
  29. Gomez-Hidalgo N.R., Ramirez P.T., Ngo B. et al. Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clin Transl Oncol 2020;22(8):1272–9. doi: 10.1007/s12094-019-02249-x
  30. Panici P.B., Basile S., Maneschi F. et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. Gynecol Oncol 2008;100(23):1707–16. doi: 10.1093/jnci/djn397
  31. Malpica A., Euscher E.D., Hecht J.L. et al. Endometrial carcinoma, grossing and processing issues: recommendations of the International Society of Gynecologic Pathologists. Int J Gynecol Pathol 2019;38(1):9–24. doi: 10.1097/PGP.0000000000000552
  32. Abu-Rustum N.R., Zhou Q., Iasonos A. et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer 2011;21(3):511–6. doi: 10.1097/IGC.0b013e31820cc305
  33. Schwameis R., Fanfani F., Ebner C. et al. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – an international pooled analysis of three ESGO accredited centres. Eur J Cancer 2023;193:113317. doi: 10.1016/j.ejca.2023.113317
  34. Matsuo K., Klar M., Song B.B. et al. Validation of the 2023 FIGO staging schema for advanced endometrial cancer. Eur J Cancer 2023;193:113316. doi: 10.1016/j.ejca.2023.113316
  35. Imboden S., Nastic D., Ghaderi M. et al. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer. Gynecol Oncol 2021;162(2):394–400. doi: 10.1016/j.ygyno.2021.05.026
  36. Oaknin A., Bosse T.J., Creutzberg C.L. et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:860–77. doi: 10.1016/j.annonc.2022.05.009
  37. Tuninetti V., Farolfi A., Rognone C. et al. Treatment strategies for advanced endometrial cancer according to molecular classification. Int J Mol Sci 2024;25(21):11448. doi: 10.3390/ijms252111448
  38. Acharya S. Is the PORTEC 4a trial exploring too little and too late? Int J Gynecol Cancer 2025;35(1):100039. doi: 10.1016/j.ijgc.2024.100039

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.